LFG
DNLI icon

Larson Financial Group’s Denali Therapeutics DNLI Stock Holding History

Larson Financial Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977 Sell
38
-24
-39% -$493 ﹤0.01% 3325
2026
Q1 		$1.19K Buy
62
+24
+63% +$478 ﹤0.01% 3100
2025
Q4 		$627 Buy
+38
New +$641 ﹤0.01% 3066

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's DNLI Position: Q2 2026 in Review

Larson Financial Group reduced its Denali Therapeutics (DNLI) stake by 39% in Q2 2026, selling an estimated $493 and leaving 38 shares worth $977. The position accounts for ﹤0.01% of the portfolio, ranked #3325.

Larson Financial Group first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.19K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Larson Financial Group held 38 shares of Denali Therapeutics worth $977 as of Q2 2026.
  • Larson Financial Group sold 24 Denali Therapeutics shares in Q2 2026, an estimated $493.
  • Denali Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3325 holding.
  • Larson Financial Group first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Denali Therapeutics position peaked at $1.19K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.